Trendlines Group - TRNLY STOCK NEWS

Limaca Medical has launched its Precision-GI™ endoscopic automated motorized EUS biopsy device in the US market, supported by clinical trials, FDA clearance, and CMS Transitional Pass-Through (TPT) Payment award. The device is designed to obtain improved biopsy results for suspected cancers in the GI tract and adjacent organs.

A clinical trial with 40 patients at IECED Medical Center demonstrated outstanding results, showing Precision-GI's ability to provide consistent, high-quality biopsy samples with excellent tissue quality and procedural efficiency. The device's motorized, automated, rotating cutting mechanism enables superior tissue acquisition with less blood content in a single pass.

The company is initially focusing sales in the New York/New Jersey Metro area, with cases already completed at three NY metro medical centers. The TPT designation reimbursement status is facilitating broader hospital adoption with financial support.

IBI Ag has secured $6.1 million in the first tranche of its Series A funding round, led by Corteva through its Corteva Catalyst platform. Other participants include The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, along with a grant from the Israel Innovation Authority.

The company is developing bio-insecticides using single domain antibody technology, adapted from pharmaceutical applications for agricultural use. Their products target both sucking and chewing insects while maintaining a low ecological footprint and minimal impact on non-targeted organisms. The technology focuses initially on high-value crops with plans to expand to row crop solutions.

Varana Capital has led the initial closing of Arcuro Medical's Series A financing round, with participation from Trendlines and Consensus Business Group. The funding will support Arcuro's growth and innovation in the medical device industry, with the Series A remaining open for additional investment.

Arcuro Medical achieved several key milestones in 2024, including establishing a new U.S. organization, expanding distribution partnerships, submitting a 510(k) for a new product line, and surpassing 5,000 global SuperBall cases. The company is positioned for significant growth in 2025 with an enhanced product portfolio and expanded market reach.

The company will present at the MSK Innovations Pitch Event on January 8, 2025, providing investors and stakeholders an opportunity to learn more about their vision and advancements.

Limaca Medical's Precision-GI™ endoscopic biopsy device has been granted transitional pass-through (TPT) payment by CMS, effective January 1, 2025, for up to three years. The device, which received FDA Breakthrough Device Designation in 2022 and FDA clearance in August 2023, is designed to improve biopsy results for gastrointestinal cancers. The motorized, automated rotating cutting mechanism enables superior tissue acquisition with less blood content in a single pass, enhancing diagnostic efficiency. The TPT program will support broader patient access by providing additional payments to hospitals to cover adoption costs. The device began its U.S. market entry in September 2024.

ElastiMed has appointed Dr. Amir Belson to its Board of Directors. Dr. Belson brings extensive experience in the medical device industry, having founded several successful companies including Neoguide Systems (acquired by Intuitive Surgical), Vascular Pathways (acquired by C.R. Bard), and Zipline Medical (acquired by Stryker). The appointment comes as ElastiMed prepares to bring its innovative compression therapy device to market. The company focuses on developing wearable medical devices for lymphatic and venous disease patients.

Vensica Medical has secured an $11 million funding round led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie. The funding will support Phase 2 clinical trials in the US and Europe for their innovative overactive bladder (OAB) treatment. The company's proprietary technology delivers botulinum toxin A (Xeomin®) through a needle-free device directly to the bladder wall, offering a potentially less invasive alternative to traditional injections. Through its partnership with Merz, Vensica has obtained exclusive rights to Xeomin® for needle-less applications in various urologic indications.

Arcuro Medical has announced a significant milestone, surpassing 4,000 surgical cases worldwide and 1,000 cases in the U.S. with its SuperBall™ Meniscal Repair System. The current version, launched in 2022 with line extensions in 2023, addresses a full range of meniscus tear patterns. CEO Jamal Rushdy expressed excitement about the achievement and future growth prospects.

Dr. Philip Davidson, Arcuro's Medical Director, highlighted the system's unique tensioning mechanism, which provides superior strength and reduced complications compared to other devices. Arcuro has recently made key hires in the U.S., including Jamal Rushdy as CEO and Nick Tonno as Sales Director, to focus on commercial growth. The company plans to provide updates at upcoming industry events in Las Vegas.

Dasyo, a pioneer in noninvasive medical aesthetics technologies, has appointed Domenic (Dom) Serafino as Executive Board Chair. Serafino brings extensive industry experience, having co-founded and led Venus Concept Inc. to over $100 million in annual revenues. He was also instrumental in Syneron Medical Corp's successful IPO. Dasyo, funded by the Israel Innovation Authority and The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), is developing a groundbreaking non-surgical breast lift product using proprietary technology for noninvasive directional skin tightening. This appointment is expected to significantly enhance Dasyo's strategic direction and growth potential in the aesthetics medical device sector.

Ceretrieve announced successful results of its multicenter, single-arm study for its aspiration catheter, aimed at treating acute ischemic stroke (AIS) caused by large vessel occlusion (LVO).

The study involved 20 patients and achieved 100% Complete/Near-Complete Perfusion with the Gen 2 device, far exceeding the 30%-40% rate of current gold-standard devices.

Ceretrieve's device allows single-pass clot removal and full blood flow restoration, ensuring high safety by minimizing the risk of clot fragments moving further into the brain.

The technology demonstrated superior performance compared to existing devices, highlighting its potential to significantly improve post-stroke patient outcomes.